CURE bleeding criteria: Difference between revisions
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Bleeding}} | {{Bleeding}} | ||
{{CMG}} | {{CMG}} | ||
==CURE Clinical Trials:== | ==CURE Clinical Trials:== | ||
The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial | |||
Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events<ref name="pmid16908769">{{cite journal| author=Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S| title=Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | journal=Circulation | year= 2006 | volume= 114 | issue= 8 | pages= 774-82 | pmid=16908769 | doi=10.1161/CIRCULATIONAHA.106.612812 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16908769 }} </ref> | |||
{{cquote| | {{cquote| | ||
*'''Major Bleeding''' | |||
*'''Major | |||
Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of | Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of | ||
intravenous inotropic agents) | intravenous inotropic agents) | ||
| Line 20: | Line 16: | ||
*'''Minor''' | *'''Minor''' | ||
Led to discontinuation of study drug }} | Led to discontinuation of study drug }} | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
[[Category:primary care]] | |||
[[Category:Medical emergencies]] | [[Category:Medical emergencies]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[ | [[Category:Needs overview]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 16:43, 27 March 2013
|
Bleeding Microchapters |
|
Treatment |
|---|
|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
|
Perioperative Bleeding |
|
CURE bleeding criteria On the Web |
|
American Roentgen Ray Society Images of CURE bleeding criteria |
|
Risk calculators and risk factors for CURE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
CURE Clinical Trials:
The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial
Clopidogrel In Unstable Angina To Prevent Recurrent Ischemic Events[1]
| “ |
Life-threatening (fatal, intracranial, requiring surgical intervention, results in substantial hypotension requiring the use of intravenous inotropic agents) Hemoglobin decrease ≥5 g/dL or required ≥4 U of blood Other major bleeding Transfusion of 2–3 U, intraocular
Led to discontinuation of study drug |
” |
References
- ↑ Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006). "Adverse impact of bleeding on prognosis in patients with acute coronary syndromes". Circulation. 114 (8): 774–82. doi:10.1161/CIRCULATIONAHA.106.612812. PMID 16908769.